87. Hamblin T.J., Davis Z.A., Oscier D.G. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia – long-term follow up of patients with different percentages of mutations // Br. J. Haematol. 2008. Vol. 140, N 3. P. 320–323.
88. Davis Z., Forconi F., Parker A., Gardiner A., Thomas P., Catovsky D. et al. The outcome of chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity // Br. J. Haematol. 2016. Vol. 173, N 1. P. 127–136.
89. Raponi S., Ilari C., Della Starza I., Cappelli L.V., Cafforio L., Piciocchi A. et al. Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations // Br. J. Haematol. 2020. Vol. 189, N 5. P. 853–859.
90. Sutton L.A., Hadzidimitriou A., Baliakas P., Agathangelidis A., Langerak A.W., Stilgenbauer S. et al. Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification // Haematologica. 2017. Vol. 102, N 6. P. 968–971.
91. Rossi D., Rasi S., Spina V., Bruscaggin A., Monti S., Ciardullo C. et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia // Blood. 2013. Vol. 121, N 8. P. 1403–1412.
92. International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data // Lancet Oncol. 2016. Vol. 17, N 6. P. 779–790.
93. Delgado J., Doubek M., Baumann T., Kotaskova J., Molica S., Mozas P. et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI // Am. J. Hematol. 2017. Vol. 92, N 4. P. 375–380.
94. Baliakas P., Moysiadis T., Hadzidimitriou A., Xochelli A., Jeromin S., Agathangelidis A. et al. Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia // Haematologica. 2019. Vol. 104, N 2. P. 360–369.
95. Condoluci A., Terzi di Bergamo L., Langerbeins P., Hoechstetter M.A., Herling C.D., De Paoli L. et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia // Blood. 2020. Vol. 135, N 21. P. 1859–1869.
96. Baliakas P., Hadzidimitriou A., Sutton L.A., Rossi D., Minga E., Villamor N. et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia // Leukemia. 2015. Vol. 29, N 2. P. 329–336.
97. Rossi D., Gaidano G. The clinical implications of gene mutations in chronic lymphocytic leukaemia // Br. J. Cancer. 2016. Vol. 114, N 8. P. 849–854.
98. Gaidano G., Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment // Hematology Am. Soc. Hematol. Educ. Program. 2017. Vol. 2017, N 1. P. 329–337.
99. Rossi D., Terzi-di-Bergamo L., De Paoli L., Cerri M., Ghilardi G., Chiarenza A. et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia // Blood. 2015. Vol. 126, N 16. P. 1921–1924.
100. Fischer K., Bahlo J., Fink A.M., Goede V., Herling C.D., Cramer P. et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial // Blood. 2016. Vol. 127, N 2. P. 208–215.
101. Thompson P.A., Tam C.S., O’Brien S.M., Wierda W.G., Stingo F., Plunkett W. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309.
102. Burger J.A., Tedeschi A., Barr P.M., Robak T., Owen C., Ghia P. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia // N. Engl. J. Med. 2015. Vol. 373, N 25. P. 2425–2437.
103. Fischer K., Al-Sawaf O., Bahlo J., Fink A.M., Tandon M., Dixon M. et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions // N. Engl. J. Med. 2019. Vol. 380, N 23. P. 2225–2236.
104. Shanafelt T.D., Wang X.V., Kay N.E., Hanson C.A., O’Brien S., Barrientos J. et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia // N. Engl. J. Med. 2019. Vol. 381, N 5. P. 432–443.
105. Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L. et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial // Lancet Oncol. 2019. Vol. 20, N 1. P. 43–56.
106. Best O.G., Gardiner A.C., Davis Z.A., Tracy I., Ibbotson R.E., Majid A. et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease // Leukemia. 2009. Vol. 23, N 1. P. 212–214.
107. Baliakas P., Jeromin S., Iskas M., Puiggros A., Plevova K., Nguyen-Khac F et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact // Blood. 2019. Vol. 133, N 11. P. 1205–1216.
108. Rossi D., Spina V., Cerri M., Rasi S., Deambrogi C., De Paoli L. et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome // Clin. Cancer Res. 2009. Vol. 15, N 13. P. 4415–4422.
109. Gounari M., Ntoufa S., Apollonio B., Papakonstantinou N., Ponzoni M., Chu C.C. et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8 // Blood. 2015. Vol. 125, N 23. P. 3580–3587.
110. Baliakas P., Agathangelidis A., Hadzidimitriou A., Sutton L.A., Minga E., Tsanousa A. et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations // Blood. 2015. Vol. 125, N 5. P. 856–859.